Three-day ODAC to review data from confirmatory trials of PD-1/PD-L1 drugs marketed under accelerated approval

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA will hold a three-day meeting of the Oncologic Drugs Advisory Committee April 27-29 to consider five indications that received accelerated approvals, but that have not been shown to produce a clinical benefit in confirmatory trials.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Joni D. Nelson, assistant director for the Office of Workforce Development at the MUSC Hollings Cancer Center, remembers the exact day a switch went off in her head and her career took a turn towards finding ways to improve public health.
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login